AFP and liver cancer: The baseline characteristics of the patients treated with sorafenib or SBRT were well balanced and no significant differences were noted with respect to sex, age, ECOG performance status, plasma levels of α-fetoprotein (AFP), Barcelona Clinic Liver Cancer staging B and C. However, the percentage of Child-Pugh class A liver function, extrahepatic spread and vascular invasion were higher in SHARP trial compared to the Phase I/II trial (Table 3).